Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.57 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.57 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.57 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.57 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.57 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.57 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.57 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789262 | 0.88 | FYN (0.51) | HDAC4HDAC2HDAC8CYP3A4CYP1A1 | |
| SCHEMBL29384037 | 0.88 | CYP1A1 (0.72) | HDAC4HDAC2HDAC8CYP3A4CYP1A1 | |
| SCHEMBL6259929 | 0.87 | CYP3A4 (0.56) | HDAC4HDAC2HDAC8CYP3A4CYP1A1 | |
| SCHEMBL982929 | 0.87 | CYP3A4 (0.77) | HDAC4HDAC2HDAC8CYP3A4CYP1A1 | |
| SCHEMBL3790187 | 0.85 | CYP3A4 (0.58) | HDAC4HDAC2HDAC8CYP3A4CYP1A1 | |
| SCHEMBL14003309 | 0.83 | ALDH1A1 (0.50) | HDAC4HDAC2HDAC8CYP3A4ALDH1A1 | |
| SCHEMBL3789651 | 0.81 | ALDH1A1 (0.58) | CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8 | |
| SCHEMBL1039794 | 0.81 | HTR7 (0.55) | CYP3A4CYP1A1CYP1A2CYP2E1CYP2C8 | |
| SCHEMBL2783622 | 0.81 | DHFR (0.55) | HDAC4HDAC2HDAC8CYP3A4ALDH1A1 | |
| SCHEMBL29572032 | 0.80 | KDM4E (0.64) | HDAC4HDAC2HDAC8CYP3A4CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-9499535-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| EP-2699572-B1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2237784-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | The Regents of the University of California (US) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009089508-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-16 | — | — | WO | disclosed |
| US-4670566-A | ANTIIFLAMMATORY AGENTS, ANTICOAGULANTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1987-06-02 | — | — | US | disclosed |
| EP-0089426-B1 | 2-AMINO-6-BIPHENYLACETIC ACIDS | A.H. ROBINS COMPANY, INCORPORATED (US) | 1986-06-11 | — | — | EP | disclosed |
| US-4440785-A | Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation | A. H. ROBINS COMPANY, INC. (US) | 1984-04-03 | — | — | US | disclosed |
| EP-0089426-A1 | 2-Amino-6-biphenylacetic acids | A.H. ROBINS COMPANY, INCORPORATED (US) | 1983-09-28 | — | — | EP | disclosed |
| US-4333951-A | MUSCLE RELAXANTS, ANTIINFLAMMATORY AGENTS | A. H. ROBINS COMPANY, INC. (US) | 1982-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HDAC4 3300/4885HDAC2 1409/4885HDAC8 3493/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HDAC4 4049/4885HDAC2 2094/4885HDAC8 4222/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | HDAC4 3300/4885HDAC2 1409/4885HDAC8 3493/4885 |
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | CASP7, CASP3, CASP6 | HDAC4 668/4885HDAC2 807/4885HDAC8 289/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | HDAC4 3300/4885HDAC2 1409/4885HDAC8 3493/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | HDAC4 3144/4885HDAC2 1111/4885HDAC8 2750/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | HDAC4 3481/4885HDAC2 1530/4885HDAC8 3648/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | HDAC4 3481/4885HDAC2 1530/4885HDAC8 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.